Cargando…
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
BACKGROUND: Despite the benefits biosimilars offer in terms of cost savings and patient access, healthcare professionals and patients have been reluctant to use them. Next to insufficient understanding of and trust in biosimilars, healthcare professionals and patients have questions about switching...
Autores principales: | Barbier, Liese, Simoens, Steven, Vulto, Arnold G., Huys, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669768/ https://www.ncbi.nlm.nih.gov/pubmed/33063267 http://dx.doi.org/10.1007/s40259-020-00440-z |
Ejemplares similares
-
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020) -
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019) -
Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022) -
Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
por: Barbier, Liese, et al.
Publicado: (2021) -
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)